Aradigm, a benefits platform for cell and gene therapies, launched from stealth today to make life-saving medicines affordable and accessible at a national scale. The company is debuting with a $20 million Series A funding round led by Frist Cressey Ventures, with participation from Andreessen Horowitz and Morgan Health, a division of JPMorganChase focused on employer-sponsored health care.